Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23571281 | 0.90 | CHRM1 (0.42) | EPHX2ALDH1A1EPHX1 | |
| SCHEMBL19014331 | 0.89 | CHRNB2 (0.43) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL24480964 | 0.87 | EPHX2 (0.40) | EPHX2EPHX1 | |
| SCHEMBL20635895 | 0.82 | EPHX2 (0.47) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL25934560 | 0.82 | ALDH1A1 (0.46) | ALDH1A1NPC1 | |
| SCHEMBL20813774 | 0.81 | ALDH1A1 (0.39) | EPHX2ALDH1A1NPC1EPHX1 | |
| SCHEMBL25934526 | 0.79 | KMT2A (0.43) | ALDH1A1NPC1 | |
| SCHEMBL22875130 | 0.78 | ALDH1A1 (0.50) | ALDH1A1NPC1 | |
| SCHEMBL10282539 | 0.77 | ALDH1A1 (0.67) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL7487836 | 0.77 | EPHX2 (0.53) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020458-A1 | METHOD OF TREATING ORGAN DISEASES OR DISORDERS WITH ASK1 INHIBITORS | Seal Rock Therapeutics, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11358940-B2 | K-Ras modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-20200247762-A1 | K-RAS MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-06 | — | — | US | disclosed |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2017103188-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | EPHX2 1997/4885ALDH1A1 776/4885CHRNB2 4762/4885 |
| US-20200247762-A1 | K-RAS MODULATORS | KRAS, HRAS, NRAS | EPHX2 2240/4885ALDH1A1 3564/4885CHRNB2 4485/4885 |
| US-20190119301-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | EPHX2 3082/4885ALDH1A1 3889/4885CHRNB2 4827/4885 |
| US-11358940-B2 | K-Ras modulators | KRAS, HRAS, NRAS | EPHX2 2689/4885ALDH1A1 3111/4885CHRNB2 4597/4885 |
| US-10464949-B2 | Thiazolyl-containing compounds for treating proliferative diseases | BTK, BCL9L, BCL9 | EPHX2 3082/4885ALDH1A1 3889/4885CHRNB2 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.